A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN

被引：0
|
作者：
Alt, J. [1 ]
Bischoff, H. G. [2 ]
Laack, H-E [3 ]
Leistner, R. D. [4 ]
Panse, J. [5 ]
Reinmuth, N. [6 ]
Schulz, C. [7 ]
Grohe, C. [8 ]
机构：
[1] Univ Med Mainz, Mainz, Germany
[2] Univ Hosp Heidelberg, Thoraxklin Heidelberg, Heidelberg, Germany
[3] Hamatol Onkol Hamburg, Hamburg, Germany
[4] Sozialstiftung Bamberg, Med Klin Pneumol Allergol & Schlafmed 4, Bamberg, Germany
[5] RWTH Aachen Univ Hosp, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany
[6] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[7] Klinikum Univ Regensburg, Med Klin & Poliklin 2, Regensburg, Germany
[8] Evangel Lungenklin Berlin Krankenhausbetriebs gGm, Klin Pneumol, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian
    Paz-Ares, Luis G.
    Jiang, Haiyi
    Huang, Yifan
    Dennis, Phillip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
    Paz-Ares, L.
    Jiang, H.
    Huang, Y.
    Dennis, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2398
  • [3] Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
    Cho, Daniel C.
    Mahipal, Amit
    Dowlati, Afshin
    Chow, Warren Allen
    Segal, Neil Howard
    Chung, Ki Y.
    Schneider, Bryan J.
    Nemunaitis, John J.
    Razak, Albiruni Ryan Abdul
    Tsai, Frank Yung-Chin
    Balmanoukian, Ani Sarkis
    Bazhenova, Lyudmila
    Xiao, Feng
    Angra, Natasha
    Abdullah, Shaad Essa
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
    Mok, Tony
    Schmid, Peter
    De Castro, Gilberto, Jr.
    Syrigos, Kostas
    Martin, Claudio
    Yamamoto, Nobuyuki
    Aren, Osvaldo
    Arrieta, Oscar
    Gottfried, Maya
    Jazieh, Abdul Rahman
    Ramlau, Rodryg
    Timcheva, Constanta
    Trani, Leonardo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1084 - S1084
  • [5] Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial
    Jotte, R.
    Conkling, P. R.
    Reynolds, C.
    Shah, C.
    Galsky, M.
    Klein, L.
    Fitzgibbons, J. F.
    McNally, R.
    Oliver, J. W.
    Renschler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 540 - 541
  • [6] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
    Mok, T.
    Johnson, M.
    Garon, E.
    Peters, S.
    Soria, J.
    Wang, L.
    Jarkowski, A.
    Dennis, P.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
  • [7] POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
    Thomas, M.
    Grohe, C.
    Eberhardt, W.
    Rawluk, J.
    Reck, M.
    Laack, E.
    Wesseler, C.
    Rittmeyer, A.
    Alt, J.
    Reinmuth, N.
    Griesinger, F.
    Kern, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 295 - 295
  • [8] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: updated results of a phase 2 trial
    Ettinger, David S.
    Jotte, Robert M.
    Paul, Lorigan
    Gupta, Vicram
    Garbo, Lawrence
    Alemany, Carlos
    Spigel, David R.
    Dudek, Arkadiusz Z.
    Salgia, Ravi
    McNally, Richard
    Renschler, Markus
    Oliver, Jennifer W.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S398 - S399
  • [9] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial
    Ettinger, D. S.
    Jotte, R.
    Lorigan, P.
    Gupta, V.
    Garbo, L.
    Spigel, D.
    Dudek, A. Z.
    Salgia, R.
    McNally, R.
    Renschler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 541 - 541
  • [10] Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy in ES-SCLC
    Reinmuth, Niels
    Paz-Ares, Luis
    Chen, Yuanbin
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Li, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowiczw, Andrzej
    Losonczy, Gyorgy
    Conev, Nicolay V.
    Armstrong, Jon
    Byrne, Natalie
    Shire, Norah
    Jiang, Haiyi
    Goldman, Jonathan
    Alt, Juergen
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 115 - 115
12345